Lizzi Collinge

One of my constituents, Joseph Towers, has experienced at first hand the brutality of brain cancer and the delays in treatment that affect people across the country. I am short on time, so I will say these few things directly to the Minister. The UK ranks 22nd out of 29 wealthy nations for our five-year brain cancer survival rate. Other countries are doing it better and we can improve too. One area that we need to improve immediately is access to drug trials. My constituent Joseph was simply lucky to get on to a drug trial; many are not. There are also delays in rolling out medicines once they are approved. His drug, Vorasidenib, had its approval set back by three months because of discussions on changes to its quality-adjusted life year scores. What are the solutions? We need the full-time brain cancer specialist within the national cancer plan. We need to spend the money that is already allocated and, of course, ensure future funding. People living with brain cancer need to be allowed access to trials and drugs that are not specifically designated for brain cancer. We are very short on treatments; tumours are often inoperable, so drugs are the main way forward. As the petition says, genome sequencing is vital for developing and delivering treatments. We need to understand the market forces determining which conditions get privately funded by pharmaceutical companies, and fill the gaps where needed. We also need to make sure that bureaucracy does not delay drug trials. Yes, drug trials take time to ensure safety and efficacy, but too often what takes up time is delays in approval and funding, rather than the science. When patients are excluded from a trial—for proper scientific reasons and for the veracity of the trial—I would argue for compassionate access to those drugs alongside the trial. We owe it to Joseph, to the families who have contacted us ahead of the debate and to every person who will receive this devastating diagnosis to do better and to move far more quickly than we are moving today.